Read Time: 2 mins

2/Yield of 12-lead 24-hour ambulatory ECG monitoring in the identification of a spontaneous type 1 Brugada pattern and its prognostic value. A sub-study of the BHF RASE Brugada project

Copy Link
Published Online: Oct 9th 2012 European Journal of Arrhythmia & Electrophysiology. 2022;8(Suppl. 1):abstr2
Authors: C Scrocco (Presenting Author) – St George’s University of London, St George’s Hospital NHS Trust, London; Y Ben-Haim – St George’s University of London, St George’s Hospital NHS Trust, London; C Miles – St George’s University of London, St George’s Hospital NHS Trust, London; M Specterman – St George’s University of London, St George’s Hospital NHS Trust, London; M Tome-Esteban – St George’s University of London, St George’s Hospital NHS Trust, London; M Papadakis – St George’s University of London, St George’s Hospital NHS Trust, London; S Sharma – St George’s University of London, St George’s Hospital NHS Trust, London; ER Behr – St George’s University of London, St George’s Hospital NHS Trust, London
Quick Links:
Article Information

Background: A type 1 Brugada pattern (T1-BrS) is a recognised marker of arrhythmic risk. Twelve-lead 24-hour Holter monitoring with V1 and V2 in standard and high precordial electrocardiogram (ECG) lead (HPL) positions, can identify transient spontaneous T1-BrS pattern in BrS patients with a concealed T1-BrS at presentation.

Aim: To investigate the yield and prognostic value of 12-lead 24-hour Holter monitoring with additional high precordial ECG leads (HPL-Holter) in a large single-centre cohort of BrS patients.

Methods: A total of 278 subjects with BrS (56% male, mean age at presentation 43 ± 15 years) were included in this study, for whom complete clinical and follow-up data and HPL-Holter(s) after initial evaluation were available. Of these, 59 had a spontaneous T1-BrS pattern at presentation (Group 1) and 219 did not (Group 2), usually requiring ajmaline provocation testing to confirm the diagnosis.

Results: From 2008 to 2022, 552 HPL-Holters were recorded in the study cohort (median 2, range 1–6). In total, 43 (73%) subjects in Group 1 and 32 (15%) in Group 2 showed a T1-BrS pattern during HPL-Holter monitoring at least once; this was evident on the 1st follow-up recording in 95% of cases in Group 1 and 66% in Group 2 (median 10 months, IQR 45, range 0.5–64), with at least 2 recordings needed in 28% of subjects in this latter group. Patients with a newly identified T1-BrS in Group 2 tended to be older (mean age 48 ± 14 vs 42 ± 16 years; p=0.05) and to carry the proband status (56% vs 52%; p<0.05) than those without, whereas there were no significant differences in gender, family history of sudden cardiac death and the presence of previous symptoms. Over a median follow-up of 68 months (IQR 64), significant arrhythmic events (appropriate ICD shocks on VT/VF) occurred in 2 subjects in Group 1 (1/43 showing T1-BrS during HPL-Holter monitoring and 1/16 not showing it; p=NS) and in 4 subjects in Group 2 (2/32 with newly identified spontaneous T1-BrS and 2/187 without; p<0.05).

Conclusions: Twelve-lead 24-hour ambulatory ECG monitoring including additional HPLs can identify a transient spontaneous T1-BrS in up to 15% of the subjects without the diagnostic pattern at presentation, most during the first year after the diagnosis. In this group, the presence of a T1-BrS pattern is associated with arrhythmic events. We recommend re-evaluation with high precordial 12-lead Holter monitoring of subjects without spontaneous T1-BrS at presentation once a year for at least the first 2 years post-diagnosis. 

Further Resources

Share this Article
Related Content In Arrhythmia
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72